• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • International HTA Experience with Targeted Therapy Approvals for Lung Cancer

    Thumbnail
    View/Open
    Maraiki209093-Published.pdf (1.029Mb)
    File version
    Version of Record (VoR)
    Author(s)
    Maraiki, Fatma
    Byrnes, J
    Tuffaha, H
    Hinder, M
    Griffith University Author(s)
    Byrnes, Joshua M.
    Year published
    2019
    Metadata
    Show full item record
    Abstract
    OBJECTIVES: The aim of this study was to compare the listing success rates and time incurred to listing of recently approved lung cancer medications across Australia, Canada and England. METHODS: A comparison between the three countries was performed with respect to the listing status, time incurred for listing and differences in recommendations made for cost effectiveness. Major uncertainties and limitations that compromise health technology assessment (HTA) recommendations were identified. RESULTS: The listing success rate was found to be low across all three countries (33% Canada, 17% England and 8% Australia). Across the ...
    View more >
    OBJECTIVES: The aim of this study was to compare the listing success rates and time incurred to listing of recently approved lung cancer medications across Australia, Canada and England. METHODS: A comparison between the three countries was performed with respect to the listing status, time incurred for listing and differences in recommendations made for cost effectiveness. Major uncertainties and limitations that compromise health technology assessment (HTA) recommendations were identified. RESULTS: The listing success rate was found to be low across all three countries (33% Canada, 17% England and 8% Australia). Across the HTA agencies' reviews, comparators were either dissimilar or altered for effectiveness and/or economic analysis. Overall, limited evidence was found for all indications, and uncertainties were identified due to indirect analyses (70%) and survival extrapolation (100%). Although most of the indications were concluded to be not cost effective, some were subsequently listed (47%) at a reduced price and/or with a specific access programme. CONCLUSIONS: This study demonstrated a low listing success rate for novel lung therapies internationally within different HTA jurisdictions. Major uncertainties that are resistant to available solutions seem to be common across different countries; thus, international solutions would be beneficial.
    View less >
    Journal Title
    PharmacoEconomics - Open
    Volume
    3
    Issue
    1
    DOI
    https://doi.org/10.1007/s41669-018-0088-x
    Copyright Statement
    © The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
    Subject
    Health economics
    Social Sciences
    Science & Technology
    Life Sciences & Biomedicine
    Economics
    Health Care Sciences & Services
    Publication URI
    http://hdl.handle.net/10072/387573
    Collection
    • Journal articles

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E
    • TEQSA: PRV12076

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander